Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury
Authors:
- Wan Soo KimWKWan Soo Kim
- Sang Soo LeeSLSang Soo Lee
- Chang Min LeeCLChang Min Lee
- Hong Jun KimHKHong Jun Kim
- Chang Yoon HaCHChang Yoon Ha
- Hyun Jin KimHKHyun Jin Kim
- Tae Hyo KimTKTae Hyo Kim
- Woon Tae JungWJWoon Tae Jung
- Ok Jae LeeOLOk Jae Lee
- Jeong Woo HongJHJeong Woo Hong
- Hyun Seon YouHYHyun Seon You
- Hyun Chin ChoHCHyun Chin Cho
Open Access
- 1 February 2016
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 16 (1) , 1-7
Abstract
The risk of anti-tuberculosis (TB) drug-induced liver injury (DILI) in patients with chronic viral hepatitis (CVH) is not clear. The aim of this study was to investigate incidence and risk factors associated with TB DILI in CVH and non-CVH patients. Retrospectively, a total of 128 CVH patients who received anti-TB medication from January 2005 to February 2014 were reviewed. Among these, 83 patients had hepatitis B virus (HBV), 41 patients had hepatitis C virus (HCV) and 4 patients were dual hepatitis B and hepatitis C virus co-infected (HBV + HCV) with 251 non-CVH patients who received anti-TB medication selected as the controls. There were no human immunodeficiency virus co-infected patients. Risk factors for DILI were analyzed using cox regression analysis. The incidence of DILI was significantly higher in the HCV group (13/41 [31.7 %], p < 0.001) and HBV + HCV groups (3/4 [75.0 %], p = 0.002) compared to the control group (25/251 [10.0 %]). The incidence of transient liver function impairment in the hepatitis B virus group was higher than in the control group (18/83 [21.7 %] vs. 27/251 [10.8 %] p = 0.010), but not in DILI (11/83 [13.3 %] vs. 25/251 [10.0 %], p = 0.400). In total patients, HCV, HBV + HCV co-infection, older age, and baseline liver function abnormality were independent factors of DILI. It is recommended to carefully monitor for DILI in patients with HCV or HBV/HCV co-infection, older age, and baseline liver function abnormality.Keywords
This publication has 29 references indexed in Scilit:
- Outcome and determinants of mortality in 269 patients with combination anti‐tuberculosis drug‐induced liver injuryJournal of Gastroenterology and Hepatology, 2012
- The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic populationLiver International, 2011
- Impacts of Vaccination on Hepatitis B Viral Infections in Korea over a 25-Year PeriodIntervirology, 2010
- Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date reviewJournal of Gastroenterology and Hepatology, 2007
- Non‐alcoholic fatty liver disease: Further expression of the metabolic syndromeJournal of Gastroenterology and Hepatology, 2007
- Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberclosis treatmentPharmacological Research, 2005
- Hepatotoxicity of Rifampin-Pyrazinamide and Isoniazid Preventive Therapy and Tuberculosis TreatmentClinical Infectious Diseases, 2004
- Antituberculosis drug-related liver dysfunction in chronic hepatitis B infectionHepatology, 2000
- A prospective clinical study of isoniazid‐rifampicin‐pyrazinamide‐induced liver injury in an area endemic for hepatitis BJournal of Gastroenterology and Hepatology, 1997
- Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.Thorax, 1996